Ganeden warning letter revisited
This article was originally published in The Tan Sheet
Executive Summary
FDA reposted a warning letter on its Web site for Ganeden Biotech. FDA removed the 1letter in March while it was in discussions with Ganeden (2"The Tan Sheet" March 5, 2007, In Brief). An FDA spokesperson says no changes were made to the letter. The letter states some of the firm's Digestive Advantage products are misbranded foods and unapproved news drugs. The products were labeled as medical foods, which FDA says is incorrect...
You may also be interested in...
Ganeden Biotech warning letter
The FDA warning letter sent to medical foods marketer Ganeden Biotech and reported in the Feb. 26 issue of "The Tan Sheet" has been removed from the agency's Web site. An FDA spokesperson told "The Tan Sheet" the letter was issued by the agency's Cincinnati office, but FDA is now in discussions with the firm over whether to withdraw the letter. The spokesperson noted that, as far as FDA is concerned, a letter was issued, and the decision to withdraw the letter was FDA's (1"The Tan Sheet" Feb. 26, 2007, In Brief)...
J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Woodcock To Be Acting US FDA Commissioner; Sharfstein Tops Biden's List Of Candidates For Post
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: